about
Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabResults of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.Alteration status and prognostic value of MET in head and neck squamous cell carcinoma.A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcomaRole of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma.Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancerPD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysisPTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma.Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer.Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy.A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue SarcomaRisk factors and prognosis of pulmonary complications after endoscopic submucosal dissection for gastric neoplasiaMarked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC TrialReal-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer
P50
Q33761681-DEB26DE7-EDFF-41F8-B4D6-385509EF2685Q36187013-26765AEE-812C-4446-AE0B-16912B7A1E8AQ36769011-2D54DC6A-0B6D-42D2-8852-09386F7D1CE0Q37061363-84F8301C-32A8-4A1F-A3DC-018B36DC0268Q37367458-5099B691-BB5E-4163-BD81-FB603455DB8DQ37514050-DF6A8992-B6D2-4E49-B981-001875FD081AQ38417869-9DBD87B4-208F-4026-995D-7F2E1AD8F1B0Q38821431-7A08DBFC-99A4-4793-8881-266A8AF7F4E4Q41594853-1455788D-11D2-41A5-97B8-5DD0CA74D17EQ41924893-266CF438-CDFA-402B-A473-90ED9C62FEC6Q41959108-4C16D435-3D6D-41EA-967E-5350FB798F6FQ42369181-52FD46CC-443F-4F72-9357-352173226616Q42371507-AB606DF7-BA10-430B-8934-E6EC61AFADA6Q47838777-60F72F1F-8426-4EE2-8A17-2A31C48B15D4Q49550546-D3808ABF-40AF-4940-BDCB-B6C4095793DAQ51147046-9A9D05A7-1C29-4835-8F6B-923805309977Q52147418-0A74A382-CAF1-4F11-B6F8-CF8DC7870954Q53607051-50F7073F-F68B-4B81-B1EC-54F274889B07Q53641389-A1A66E58-EB70-40B7-9835-63B73DEA50F8Q55381676-4AF2EDE3-BAB4-4EE1-859D-E7A2B02B1124Q58600783-7B85DAA0-BE94-43D3-AF62-23F58307B20FQ85008303-6B39FD7F-E421-42A8-AE95-3B80F234EE97Q90553378-D17D6EE7-822C-4D18-87C3-6AA4C549AF01Q92263247-EFD19E57-7E24-41D2-A306-F81AA2BE2D27
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Su Jin Heo
@en
Su Jin Heo
@nl
type
label
Su Jin Heo
@en
Su Jin Heo
@nl
prefLabel
Su Jin Heo
@en
Su Jin Heo
@nl
P31
P496
0000-0002-0615-5869